First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) have transformed the treatment of advanced non-small cell lung cancer (NSCLC) [1–4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.